ATS 2019 Virtual Final Program

P152 Defining the Preliminary Function of Siglec-F Expressed on Mouse Alveolar Macrophages In Vitro/ T. Liu, Y.-H. Feng, F.-P. Wang, H. Mao, Chengdu, China, p.A6174 P153 Pseudomonas Aeruginosa Protease and Elastase Activity Are Common in ICU Respiratory Isolates/ J.A. Zupetic, R. DeSensi, Y. Qu, W. Bain, R. Mettus, Y. Doi, S.M. Nouraie, J. Lee, Pittsburgh, PA, p.A6175 BASIC • CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION D34 CYSTIC FIBROSIS AND BRONCHIECTASIS: CLINICAL AND MECHANISTIC STUDIES 9:15 a.m. - 3:30 p.m. KBHCCD Area F (Hall F, Level 2) Viewing: Posters will be on display for entire session. Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators. Facilitator : C. Richards, MD, Boston, MA P831 Association of Tumour Growth Factor-Beta 1 Levels with dF508 Genotype and Clinical Phenotype of Cystic Fibrosis/ M. Singh, S. Sagwal, M. Singh, Chandigarh, India, p.A6176 P832 Evaluating Peripheral Blood Eosinophilia and Health Outcomes in Hospitalized Cystic Fibrosis Patients with Pulmonary Exacerbations/ A. Siedlecki, B. Quon, S.J. Tebbutt, D.R. Dorscheid, Vancouver, Canada, p.A6177 P833 Evaluation of Dehydroepiandrosterone Sulfate (DHEA-S) Levels in Cystic Fibrosis/ L. Shaffer, S. Abid, R. Jain, Dallas, TX, p.A6178 P834 Cystic Fibrosis Disease Severity Correlates with Biomarkers of Elastin Degradation/ A.J. Dabo, S. Ma, P. Geraghty, C. McCarthy, G. McElvaney, G. Turino, Brooklyn, NY, p.A6179 P835 High Prevalence of Staphylococcus Aureus Enterotoxin Gene Cluster Superantigens in Cystic Fibrosis Clinical Isolates/ A.J. Fischer, D. Limoli, S. Kilgore, P. Schlievert, Iowa City, IA, p.A6180 P836 eNose Technology for Detection of Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients/ A. Lammers, R. Kos, R. de Vries, P. Brinkman, J.W.F. Dagelet, N.W. Rutjes, C.J. Majoor, S.W.J. Terheggen-Lagro, E.J.M. Weersink, L.D.J. Bos, P.J. Sterk, A.H. Maitland-van der Zee, A.H. Neerincx, Amsterdam, Netherlands, p.A6181 P837 Effect of Bicarbonate on Cathelicidin and Neutrophil Killing of Pseudomonas Aeruginosa/ R. Siew, K. Akong, V. Nizet, La Jolla, CA, p.A6182 P838 Evolutionary Phylogenomics Identified Hypermutable Isolates of Nontuberculous Mycobacteria in a Cystic Fibrosis Chronic Infection/ J. Bouso, A. Moustafa, R. Ehrlich, A. Narechania, J. Chang Mell, P.J. Planet, Philadelphia, PA, p.A6183 P839 Increased NADPH in Human PCD Airway Epithelial Cells: Does the Reducing Environment in Cells with Ciliary Dysfunction Lead to Decreased NO Evolution?/ N. Marozkina, L. Smith, C. Cotton, B.M. Gaston, Cleveland, OH, p.A6184 P840 Neutrophil Function May Impact Sex Based Differences in Disease Outcomes in Cystic Fibrosis/ M. Bose, S. Abid, A. Keller, L. Fernandez, L. Schumacher, O. Cavazos, R. Jain, Dallas, TX, p.A6185 Facilitator : P.K. Mohabir, MD, Stanford, CA P841 Metabolic Reprogramming of the Cystic Fibrosis Neutrophil Drives Interleukin-1ß via the NLRP3 Inflammasome/ O.J. McElvaney, Z. Zaslona, E. Palsson-McDermott, C. Gunaratnam, L.A.J. O’Neill, E.P. Reeves, N.G. McElvaney, Dublin, Ireland, p.A6188 P842 Airway Stem Cell Heterogeneity in Advanced Cystic Fibrosis/ W. Xian, S. Niroula, F. Mckeon, Houston, TX, p.A6189 P843 Novel Anti-Aging Strategies to Inhibit the Effect of Bronchial Cell Senescence on Mucociliary Dysfunction/ S. Krick, J. Garth, A.T. Adewale, R.-J. Shei, L.P. Tang, E.S. Helton, R. Denson, R. Zaharias, G. King, J. Sailland, L. Kunzi, N. Baumlin, M.A. Salathe, S.M. Rowe, J.W. Barnes, Birmingham, AL, p.A6190 P844 Use of Quantitative Proteomic Analysis of CF and Non-CF Human Bronchial Epithelial (HBE) Cell Apical Secretome (AS) to Identify Changes in Innate Immunity of Lungs/ K. Salka, A. Panigrahi, K. Brown, M.A. Arroyo Morr, G.R. Nino, M. Rose, G.F. Perez, Washington, DC, p.A6191 P845 Electric Cell- Substrate Impedance Sensing Reveals Defective Permeability in Cystic Fibrosis Bronchial Epithelial Cells/ C. Sendon, C. DiPietro, H. Oez, C. Barone, R. Pierce, M.E. Egan, E.M. Bruscia, New Haven, CT, p.A6192 P846 A Precision Approach to Analyzing Inflammatory-Induced Glycogene Changes in Cystic Fibrosis/ J.W. Barnes, C. Sesler, E.S. Helton, M. Mazur, R. Denson, R. Zaharias, A. Adewale, S.M. Rowe, S. Krick, Birmingham, AL, p.A6193 P847 The Structure the Calcium Activated Chloride Channel Regulator 1 (CLCA1) VWA Domain and Its Translation Application to Potentiate TMEM16A Anion Channel Activity in Primary CF Airway Cells/ T. Brett, K.N. Berry, M. Sala-Rabanal, D.E. Byers, E. Katz, C.G. Nichols, J. Alexander-Brett, St. Louis, MO, p.A6194 P848 The Impact of BAL Fluid Gliotoxin on Mesenchymal Stromal-Based Cell Therapies/ S. Rolandsson Enes, S.C. Abreu, T.H. Hampton, R.A. Cramer Jr, B.A. Stanton, M. Wargo, D.J. Weiss, Burlington, VT, p.A6195 P849 Oligotherapeutics to Improve CFTR Correction/ F. Lutful Kabir, S. Sasaki, S. Guo, N. Ambalavanan, S.M. Rowe, W.T. Harris, Birmingham, AL, p.A6196 P850 iPSC-Derived Bronchospheres as a Novel Platform for Cystic Fibrosis Drug Development/ A. Berical, M. Beermann, D.C. Thomas, N. Ranallo, P.G. McNally, K.J. Hurley, S.H. Randell, D.N. Kotton, F.J. Hawkins, Boston, MA, p.A6197 P851 Alpha-1 Antitrypsin Imparts an Anti-Inflammatory Effect Without Increasing Bacterial Burden in Models of Antibiotic-Treated Cystic Fibrosis P. Aeruginosa Infection/ S. Gellatly, N. Schaunaman, S. Caceres, P.E. Bratcher, K. Ward, D.P. Nichols, K. Malcolm, H.W. Chu, Denver, CO, p.A7465 ATS 2019 • Dallas, TX WEDNESDAY • MAY 22 335 WEDNESDAY MORNING